Clinical trials: Bacterial Co-infection
Neisseria Meningitidis, Haemophilus Influenzae Type b
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' Hib-MenCY-TT (MenHibrix®) vaccine co-administered with Rotarix, Prevnar 13 and Havrix as compared to PedvaxHIB…
- Trial name
- NCT01978093
- Testing
- Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®
- Where
- 26 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anthrax
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
This study is designed to evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when administered orally, prior to, and following, the intramuscular (IM) administration of a two-dose schedule of AV7909…
- Trial name
- NCT04067011
- Testing
- Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909
- Where
- 4 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Gonorrhoea
Cefixime / Azithromycin pK Study
This is a PK study of a multi-dose oral cefixime regimen (three 800 mg doses given on a q 8-hour schedule) alone and also co administered with a single 1000 mg oral dose of azithromycin, both within a 24-hour period, in order to…
- Trial name
- NCT02708992
- Testing
- Azithromycin, Cefixime
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Bacterial Co-infection
Host Immunity, Plasmodium and Pathogens Co-Infections
Few studies have focused on malaria co-infections, mainly caused by Plasmodium falciparum, occurring mainly in children under 5 years of age in sub-Saharan Africa.
- Trial name
- HIPPI (NCT06769815)
- Testing
- Blood sample, Urine sample, oropharyngeal sample
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Tuberculosis, Pulmonary, HIV/AIDS
RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection
Although tuberculosis is a treatable disease, it is currently the infectious disease with the highest mortality in the world. It is estimated that one-third of the world's population is infected.
- Trial name
- RIPENACTB (NCT03281226)
- Testing
- RIPE (2m) and RI (4m), RIPE+NAC (2m) and RI (4m)
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Tuberculosis, HIV
Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection
We propose a first interaction study between efavirenz (EFV) and R20mg/Kg taking into consideration the absence of data about R induction at this dose.
- Trial name
- RIFAVIRENZ (NCT01986543)
- Testing
- drug administration
- Where
- Uganda
- Volunteers
- 105 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Infections, Streptococcal, Streptococcus Pneumoniae
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of…
- Trial name
- NCT00814710
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Tritanrix-HepB/Hib, Hiberix
- Where
- 4 sites in India
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease, Invasive
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13)…
- Trial name
- NCT05934890
- Testing
- Walvax PCV13-TT, Pfizer PCV13
- Where
- 2 sites in Indonesia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Tuberculosis
Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota
This will be the first study to evaluate the use of Nyaditum resae® as a potential agent for reducing antibiotic-associated gut dysbiosis in patients with drug-susceptible TB, and potentially improving clinical and…
- Trial name
- NCT03851159
- Testing
- Nyaditum resae®, Mannitol
- Where
- 2 sites in South Africa
- Volunteers
- 48 people
- Sponsor
- University of Stellenbosch
Acute Respiratory Tract Infections, Pneumonia
Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections
Respiratory syncytial virus (RSV) infection and bacterial co-infection are the most common causes of pneumonia. Currently, there is no vaccine available for RSV prevention, and the use of the antiviral medication ribavirin is not…
- Conditions
- Acute Respiratory Tract Infections, Pneumonia, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT05929599
- Testing
- 0.9% NaCl physiological saline, LiveSpo Navax
- Where
- Vietnam
- Volunteers
- 120 people
- Sponsor
- National Children's Hospital, Vietnam
COVID-19
Risks of Bacterial and Fungal Superinfection in Patients With COVID-19
Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks…
- Trial name
- NCT05256316
- Testing
- Previously admitted COVID-19 patients in intensive care units
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 790 people
- Sponsor
- The University of Queensland
Tuberculosis, Pulmonary, HIV Coinfection
Pharmacist-Led Intervention to Improve TB Treatment Adherence
The goal of this clinical trial is to compare the adherence of co-morbid patients in control and experimental group The main question[s]it aims to answer are: 1.
- Trial name
- RA-15041995 (NCT06608069)
- Testing
- Educational counselling
- Where
- 2 sites in Malaysia
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Tuberculosis, Alcohol Use Disorders
Effectiveness of Alcohol Interventions Among Tuberculosis (TB) Patients in Tomsk Oblast, Russia
The primary goal of this study is to assess the effectiveness of two alcohol interventions administered singly or in combination as an integrated component of TB care provided to patients with co-occurring TB and AUDs in Tomsk…
- Trial name
- IMPACT (NCT00675961)
- Testing
- Brief Counseling Intervention (BCI), Naltrexone, BCI + Naltrexone
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Sepsis, Systemic Inflammatory Response Syndrome
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
The aim of this project is to test the utility of The Gene Z device (as of 2018 Gene Z no longer being used), now using In-Dx and other rapid identification techniques that the investigators have developed in the lab on…
- Conditions
- Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial
- Trial name
- NCT01904188
- Testing
- Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)
- Where
- 2 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Michigan State University
Typhoid, Cholera
Co-administration Study of OCV, TCV and MR
An open-label, randomized controlled, non-inferiority study of co-administration of OCV, TCV and MR vaccines among children 12 to 59 months of age in Dhaka, Bangladesh will be conducted.
- Conditions
- Typhoid, Cholera, Measles, Rubella
- Trial name
- NCT05771779
- Testing
- Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR)
- Volunteers
- 2,117 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
HIV Infections, Tuberculosis
Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients
The study will investigate whether combination antiretroviral therapy of raltegravir and 3TC/ABC is effective and safe to use in tuberculosis (TB)/HIV co-infected adults receiving rifabutin-containing, first-line antituberculous…
- Trial name
- NCT01059422
- Testing
- Raltegravir; Abacavir/Lamivudine
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Central Institute of Epidemiology, Moscow, Russia
Viral Pneumonia, Bacterial Pneumonia
Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
The purpose of this study is to determine whether a protein called TREM-1 can be used to differentiate viral and bacterial pneumonias in children who are on ventilator support.
- Trial name
- NCT00645619
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
HIV Infections, Tuberculosis
Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
To assess safety, efficacy and impact of Lopinavir/ritonavir 400/100mg bid or Lopinavir/ritonavir 600/150mg bid in combination with rifampicin-containing anti-TB therapy.
- Trial name
- NCT01138202
- Testing
- LPV/r
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Tuberculosis
Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
Higher doses of rifampicin has been associated with a faster drop in bacterial load over time, and shorter treatment regimens with high dose rifampicin are being proposed.
- Trial name
- SAEFRIF (NCT03982277)
- Testing
- Rifampin 300 Mg Oral Capsule
- Where
- Uganda
- Volunteers
- 130 people
- Sponsor
- Makerere University
HIV Infections, Immune Activation
The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study
Background Commencement of lifelong highly active antiretroviral therapy (HAART) immediately after HIV diagnosis (option B+), for treatment of human immunodeficiency virus (HIV), has greatly improved maternal-infant health in sub…
- Conditions
- HIV Infections, Immune Activation, Comorbidities
- Trial name
- UZ-CHS-BC (NCT04087239)
- Testing
- HIV
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Zimbabwe